New compound disrupts survival pathways in aromatase inhibitor-resistant breast cancer cells
“The ability of PCAIs to mitigate various cancer hallmarks in the various cancer cell lines has been well established”
2025-08-13
(Press-News.org)
“The ability of PCAIs to mitigate various cancer hallmarks in the various cancer cell lines has been well established.”
BUFFALO, NY – August 13, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.”
In this study, led by first author Jassy Mary S. Lazarte and corresponding author Nazarius S. Lamango from Florida A&M University College of Pharmacy and Pharmaceutical Sciences, researchers investigated a new class of compounds called polyisoprenylated cysteinyl amide inhibitors (PCAIs) as a potential treatment for aromatase inhibitor (AI) therapy resistant breast cancer. Aromatase inhibitors are a common treatment for estrogen receptor-positive (ER+) breast cancer, but many patients eventually develop resistance, leaving fewer therapeutic options.
The study focused on a PCAI compound called NSL-YHJ-2-27, which was tested in long-term letrozole-treated breast cancer cells (LTLT-Ca), an experimental model of AI therapy resistance. NSL-YHJ-2-27 activated two major signaling pathways, MAPK and PI3K/AKT. Although these pathways typically support cancer cell survival, their overstimulation by PCAIs led to increased oxidative stress, damaging the cells and inducing cell death by apoptosis. The compound also reduced levels of RAC1 and CDC42, proteins involved in maintaining cell shape and movement. These alterations resulted in cytoskeletal disruption and reduced structural integrity, making the cancer cells more vulnerable and less capable of spreading. Importantly, the effects of NSL-YHJ-2-27 persisted after the compound was removed, suggesting long-term control over AI resistant cancer cells may be possible.
“PCAIs inhibited cell proliferation and colony formation by 95% and 74%, respectively, increased active caspase 7 and BAX 1.5-fold and 56%, respectively. NSL-YHJ-2-27 (10 μM) induced LTLT-Ca spheroid degeneration by 61%.”
As a new class of targeted molecules, PCAIs represent an innovative approach distinct from traditional endocrine therapies. Their ability to affect multiple cellular mechanisms simultaneously makes them promising candidates for future drug development.
Overall, this study presents a promising new approach for treating AI therapy-resistant breast cancer. By targeting cellular pathways that support survival and mobility, PCAIs like NSL-YHJ-2-27 could provide a novel strategy to manage advanced or resistant forms of the disease. Further research, including in vivo studies and clinical trials, will be essential to confirm these findings and evaluate their therapeutic potential.
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28759
Correspondence to: Nazarius S. Lamango – nazarius.lamango@famu.edu
Keywords: cancer, PCAIs, ROS, MAPK, PI3K/AKT, LTLT-Ca cells
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-08-13
INDIANAPOLIS -- Regenstrief Institute’s latest LOINC® content update on August 12, introduces two new linguistic variants: Arabic, for users in Jordan, and Czech, for users in the Czech Republic. With these additions, LOINC is now available in 22 languages.
“Expanding the number of supported languages improves the accessibility and adoption of LOINC around the world,” said Marjorie Rallins, DPM, M.S., executive director of Health Data Standards (HDS) at Regenstrief. “Making LOINC content available in more languages strengthens interoperability by enabling users to work with data in ...
2025-08-13
LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.
In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patients were cancer-free a year later.
“Traditionally, these patients have had very limited treatment options. This new therapy is the most effective one reported to date for the most common form of bladder cancer,” said Sia Daneshmand, MD, director of urologic oncology with Keck ...
2025-08-13
A public-private partnership between Commonwealth Fusion Systems (CFS), the U.S. Department of Energy’s (DOE) Princeton Plasma Physics Laboratory (PPPL) and Oak Ridge National Laboratory has led to a new artificial intelligence (AI) approach that is faster at finding what’s known as “magnetic shadows” in a fusion vessel: safe havens protected from the intense heat of the plasma.
Known as HEAT-ML, the new AI could lay the foundation for software that significantly speeds up the design of future fusion systems. Such software could also enable good decision-making during fusion operations by adjusting the plasma so that ...
2025-08-13
Late nights, alcohol, and smoking on weekends may be doing more than disrupting your Monday mornings, they could be triggering a newly identified sleep health concern known as ‘social apnea’, warn researchers from Flinders University.
Published in the prestigious American Journal of Respiratory and Critical Care Medicine, the international study introduces social apnea as a novel trend in sleep medicine referring to the weekend spike in Obstructive Sleep Apnea (OSA) severity, driven by lifestyle choices and irregular sleep patterns.
The research, which analysed data from over 70,000 people worldwide, found a consistent ...
2025-08-13
Florida Atlantic University’s Charles E. Schmidt College of Science has been awarded a $700,000 grant from the United States Environmental Protection Agency Gulf of America Division to support a novel research project aimed at advancing water quality monitoring in one of Florida’s most critical freshwater ecosystems.
Led by Natalia Malina, Ph.D., principal investigator and an assistant professor in FAU’s Department of Chemistry and Biochemistry within the Charles E. Schmidt College of Science, the three-year project titled, “Developing ...
2025-08-13
For years, scientists at Washington State University’s Puyallup Research & Extension Center have been working to untangle a mystery: Why do coho salmon in Puget Sound creeks seem to suffocate after rainstorms—rising to the surface, gaping, and swimming in circles before dying?
In 2018, the die-offs were linked to bits of car tires shed by friction and washed into the stormwater runoff. In 2020, researchers zeroed in on one particular chemical culprit, a tire preservative known as 6PPD.
Now, research led by WSU PhD student Stephanie ...
2025-08-13
Aqueous zinc-ion batteries (ZIBs) are gaining attention as a safer and more affordable alternative to lithium-ion batteries (LIBs). While LIBs remain the most widely used energy storage technology, they come with safety risks due to their reliance on flammable organic electrolytes. In contrast, aqueous ZIBs use water-based electrolytes, making them non-flammable, environment friendly, and more affordable. Unfortunately, during charging and discharging, zinc-anodes in ZIBs undergo repeated plating and stripping that can trigger undesirable side reactions and sharp dendrite formation. This severely impacts their ...
2025-08-13
The University of Texas at San Antonio (UTSA) announced today that it has exceeded the university’s goal of raising more than $500 million through its largest fundraising effort in university history, Be Bold: A Campaign for Our Future.
The ambitious campaign aimed to accelerate student success, advance research excellence and expand the university’s community impact. First conceived in 2017 and set to run for 10 years alongside the university’s strategic plan, the Be Bold campaign garnered support from more than 60,000 ...
2025-08-13
CHAMPAIGN, Ill. — Scientists from the Illinois Natural History Survey and the Illinois Department of Natural Resources have updated the state conservation status ranks, or S-ranks, of threatened and endangered plants in Illinois. The update includes some plants not recorded in the state for decades and finds many that, while still threatened, are doing better than previously thought.
Their findings are detailed in the Natural Areas Journal.
The 331 plants on the list are as fascinating as they are rare, said Brian Charles, an INHS scientific specialist in botany who led the multiyear effort. They include ...
2025-08-13
DARIEN, IL – The American Academy of Sleep Medicine is accepting abstracts and innovation award entries as part of Sleep Medicine Disruptors 2025, which will be held in-person in Austin, Texas, and livestreamed Friday and Saturday, Nov. 14-15.
This biennial event attracts clinicians, scientists, technology developers, start-up founders, venture capitalists, and other health care innovators. Speakers will explore technology innovation, artificial intelligence, and other disruptions that are poised to change the landscape of sleep health, patient care, and health care delivery. ...
LAST 30 PRESS RELEASES:
[Press-News.org] New compound disrupts survival pathways in aromatase inhibitor-resistant breast cancer cells
“The ability of PCAIs to mitigate various cancer hallmarks in the various cancer cell lines has been well established”
